Pharma, Biotech and Generics Industry News | The Pharmaletter
Dec 17, 2010 · 9 December 2024 The pharmacovigilance (PV) teams within the pharmaceutical industry currently report allocating 40 to 85% of budgets towards case processing. With case processing volumes growing at a rate of 10 to 15% annually, life sciences organizations are aiming to reduce costs and automate time-consuming processes while maintaining or …
Novo Nordisk settles patent lawsuit over Ozempic
Oct 8, 2024 · Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US patent lawsuit over diabetes drug Ozempic (semaglutide). The lawsuit aimed to protect Ozempic’s market exclusivity until 2032. Mylan and Natco Pharma are developing a generic version, with exclusivity for six months after approval.
Kura and Kyowa Kirin sign ziftomenib deal | The Pharmaletter
Nov 21, 2024 · San Diego, USA-based Kura Oncology (Nasdaq: KURA) and Japan’s Kyowa Kirin (TYO: 4151) have entered into a global strategic collaboration to develop and commercialize ziftomenib. Kura’s selective oral menin inhibitor is being investigated for the treatment of patients with acute myeloid leukemia ...
AstraZeneca selects Quell drug to progress in type 1 diabetes Treg …
Nov 18, 2024 · Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program.
Trump vs Harris—who's on Big Pharma's side?
Sep 22, 2024 · In the 2024 US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have criticized high drug prices, raising uncertainty for the industry. While Trump targeted generics, biosimilars, and international price comparisons during his term, Harris has been associated with pricing transparency and the Inflation Reduction Act (IRA), which ...
CatalYm gaining momentum with GDF-15 neutralizing approach
Nov 19, 2024 · German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. The company is confident that it is on to something special with its novel anti-growth differentiation factor-15 (GDF-15) approach to counteracting cancer therapy resistance and improving patient outcomes, and its lead program, the anti-GDF-15 antibody candidate, visugromab, is showing its clinical potential.
BeOne Medicines | The Pharmaletter
Formerly known as BeiGene, the company changed its name in November 2024 as part of a broader strategic growth plan. To support its expansive clinical portfolio and global growth, the company opened its $800 million flagship clinical R&D and manufacturing facility at the Princeton West Innovation Campus in Hopewell, N.J. in July 2024.
GlycoMimetics soars on news of M&A deal with Crescent Biopharma
Oct 30, 2024 · Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, GlycoMimetics - whose shares leapt 191% to $0.49 on the news - plans to operate under the name Crescent Biopharma Inc.
Ophirex - The Pharmaletter
4 days ago · Company Overview. Ophirex is advancing its investigational treatment, varespladib, as an easily portable, oral, broad-spectrum treatment for snakebite.
TGA safety warning on promethazine | The Pharmaletter
Nov 20, 2024 · Australia’s Therapeutic Goods Administration (TGA) yesterday warned that health professionals and consumers are advised that the oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be used in …